Blood marker and age linked to risk of cognitive impairment
At age 75, estimated five-year risk of mild cognitive impairment was 17% with higher blood marker levels versus 7% with lower levels.

Our read
Biomarkers- Studied:
- Cohort study of 1,644 cognitively unimpaired older adults (Multicenter)
- What changed:
- At age 75, estimated 5-year mild cognitive impairment risk was 17% with higher blood marker levels versus 7% with lower levels
- The catch:
- The featured absolute-risk estimates come from residents of one Minnesota county
- In the record:
- One of 4 papers on plasma phosphorylated tau 217 on record: 4 with results in people.
Editor of record: Boris Djordjevic · AgingResearch.News
Men and women aged 60 to 90 without cognitive impairment took part in a cohort study: 1,644 in the Mayo Clinic Study of Aging and 534 in the Alzheimer’s Disease Neuroimaging Initiative. Researchers used blood measurements and follow-up assessments to model risk of mild cognitive impairment and dementia. They measured phosphorylated tau 217, a form of the tau protein, and considered age, sex and whether participants carried a particular gene variant.
Higher blood levels and older age were linked to greater risk. At age 75, with sex and gene-variant status set to the Minnesota cohort’s average values, estimated five-year risk of mild cognitive impairment was 7% at 0.072 picograms per milliliter versus 17% at 0.324. Estimated 10-year risks were 15% and 35%, respectively.
Why it matters
Alzheimer’s-related changes can be detected years before symptoms appear. The authors suggest that individualized risk estimates could help inform prognosis and select participants for clinical trials.
Caveats
The risks were modeled in adults aged 60 to 90 who started without cognitive impairment; they do not describe risk in younger adults or people already impaired.
The paper
Mayo Clinic; for the Alzheimer’s Disease Neuroimaging Initiative
JAMA Neurology, Nov 16, 2026



Comments
Be the first to comment.